Reshma Kewalramani, Vertex CEO (Vertex)
A year out from FDA approval, Vertex looks to expand top-selling CF drug to pediatrics
About a year after getting the FDA thumbs-up for its blockbuster cystic fibrosis drug Trikafta, Vertex is picking up where it left off. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
